Similarly, in EGFR mutant NSCLC, when local SBRT was added to oligo-progressive lesions in a multi-institutional phase II trial, median PFS and OS were significantly greater of 15 months, and 20 months, respectively, than historical controls receiving systemic drugs alone. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.